Tesaro, Inc. (TSRO) Reaches $63.06 52 Week Low; Profile of 5 Analysts Covering Capstone Turbine (CPST)

January 17, 2018 - By Winifred Garcia

The stock of Tesaro, Inc. (NASDAQ:TSRO) hit a new 52-week low and has $59.91 target or 5.00% below today’s $63.06 share price. The 9 months bearish chart indicates high risk for the $3.43B company. The 1-year low was reported on Jan, 17 by Barchart.com. If the $59.91 price target is reached, the company will be worth $171.45M less. The stock decreased 3.75% or $2.46 during the last trading session, reaching $63.06. About 477,812 shares traded. Tesaro, Inc. (NASDAQ:TSRO) has risen 254.28% since January 17, 2017 and is uptrending. It has outperformed by 237.58% the S&P500.

Among 6 analysts covering Capstone Turbine Corporation (NASDAQ:CPST), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Capstone Turbine Corporation had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 14 by H.C. Wainwright. The stock of Capstone Turbine Corporation (NASDAQ:CPST) has “Hold” rating given on Friday, October 2 by Craig Hallum. The stock of Capstone Turbine Corporation (NASDAQ:CPST) earned “Hold” rating by Oppenheimer on Wednesday, June 14. Roth Capital maintained Capstone Turbine Corporation (NASDAQ:CPST) on Friday, October 27 with “Buy” rating. The stock of Capstone Turbine Corporation (NASDAQ:CPST) earned “Buy” rating by H.C. Wainwright on Wednesday, October 11. The firm has “Buy” rating given on Tuesday, July 18 by H.C. Wainwright. The company was initiated on Tuesday, November 17 by Oppenheimer. The company was maintained on Thursday, March 24 by Rodman & Renshaw. Oppenheimer upgraded Capstone Turbine Corporation (NASDAQ:CPST) rating on Wednesday, October 4. Oppenheimer has “Buy” rating and $2.0 target. Roth Capital upgraded the shares of CPST in report on Monday, September 18 to “Buy” rating. See Capstone Turbine Corporation (NASDAQ:CPST) latest ratings:

27/10/2017 Broker: Roth Capital Rating: Buy New Target: $2.0 Maintain
11/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.0 Maintain
04/10/2017 Broker: Oppenheimer Rating: Buy New Target: $2.0 Upgrade
18/09/2017 Broker: Roth Capital Rating: Buy Upgrade
10/08/2017 Broker: Roth Capital Rating: Hold New Target: $0.6500 Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.0000 Maintain
09/08/2017 Broker: Oppenheimer Rating: Hold Maintain
18/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.0000 Maintain

The stock decreased 0.13% or $0.001 during the last trading session, reaching $0.799. About 109,159 shares traded. Capstone Turbine Corporation (NASDAQ:CPST) has declined 54.23% since January 17, 2017 and is downtrending. It has underperformed by 70.93% the S&P500.

Capstone Turbine Corporation develops, makes, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. The company has market cap of $37.35 million. It offers microturbine units, components, and various accessories for applications, including cogeneration comprising combined heat and power and integrated CHP, as well as combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply. It currently has negative earnings. The companyÂ’s microturbines are also used as battery charging generators for hybrid electric vehicle applications.

Analysts await Tesaro, Inc. (NASDAQ:TSRO) to report earnings on February, 27. They expect $-2.38 EPS, up 8.46% or $0.22 from last year’s $-2.6 per share. After $-0.47 actual EPS reported by Tesaro, Inc. for the previous quarter, Wall Street now forecasts 406.38% negative EPS growth.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $3.43 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.25, from 1.46 in 2017Q2. It turned negative, as 47 investors sold Tesaro, Inc. shares while 65 reduced holdings. 44 funds opened positions while 91 raised stakes. 58.28 million shares or 5.16% more from 55.42 million shares in 2017Q2 were reported. Goldman Sachs Group Incorporated reported 336,617 shares or 0.01% of all its holdings. Franklin Resource Inc owns 0.08% invested in Tesaro, Inc. (NASDAQ:TSRO) for 1.29 million shares. Advsr Asset Mngmt accumulated 4,499 shares. Granite Point Management L P has invested 0.22% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Mutual Of America Mgmt Limited Liability Com holds 520 shares or 0% of its portfolio. Fred Alger Mngmt Inc stated it has 0.17% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Luxembourg-based Artal Grp Inc Sa has invested 0.17% in Tesaro, Inc. (NASDAQ:TSRO). Jasper Ridge Limited Partnership owns 4,028 shares. First Republic Investment Management Inc holds 5,274 shares or 0% of its portfolio. Nj State Employees Deferred Compensation Plan accumulated 6,000 shares. Strs Ohio stated it has 492 shares or 0% of all its holdings. Northern Tru Corporation stated it has 215,096 shares. Btg Pactual Global Asset Mngmt Ltd stated it has 0.15% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Zurcher Kantonalbank (Zurich Cantonalbank) reported 9,200 shares. Eventide Asset Mngmt Limited Company holds 26,000 shares or 0.19% of its portfolio.

Since September 1, 2017, it had 0 insider purchases, and 5 insider sales for $4.63 million activity. Huber Martin H. Jr. also sold $70,211 worth of Tesaro, Inc. (NASDAQ:TSRO) on Thursday, September 21. Armitage James O sold $1.17M worth of stock. The insider Oliveira Orlando sold 71 shares worth $9,419. Another trade for 14,167 shares valued at $1.91 million was made by Bogle Grant C. on Friday, September 1. 10,862 shares valued at $1.47M were sold by English Edward C on Wednesday, September 6.

Among 25 analysts covering Tesaro Inc (NASDAQ:TSRO), 14 have Buy rating, 1 Sell and 10 Hold. Therefore 56% are positive. Tesaro Inc had 64 analyst reports since August 24, 2015 according to SRatingsIntel. On Friday, August 12 the stock rating was initiated by RBC Capital Markets with “Outperform”. The firm has “Outperform” rating by FBR Capital given on Tuesday, December 27. The firm earned “Outperform” rating on Wednesday, November 15 by Leerink Swann. The firm has “Outperform” rating given on Monday, August 24 by Leerink Swann. The firm has “Hold” rating given on Wednesday, September 6 by Cowen & Co. The firm earned “Outperform” rating on Friday, August 5 by Wedbush. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Strong-Buy”. On Wednesday, July 19 the stock rating was maintained by Credit Suisse with “Buy”. The stock of Tesaro, Inc. (NASDAQ:TSRO) has “Mkt Perform” rating given on Friday, February 10 by Leerink Swann. Wedbush initiated the stock with “Outperform” rating in Thursday, January 21 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: